Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H4O6 |
Molecular Weight | 184.1031 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC(=O)C=C(O1)C(O)=O
InChI
InChIKey=PBAYDYUZOSNJGU-UHFFFAOYSA-N
InChI=1S/C7H4O6/c8-3-1-4(6(9)10)13-5(2-3)7(11)12/h1-2H,(H,9,10)(H,11,12)
Molecular Formula | C7H4O6 |
Molecular Weight | 184.1031 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Chelidonic acid (CA) is a γ-pyrone which is contained in the rhizome of Chelidonium majus L. It has multiple pharmacological effects including those of a mild analgesic, an antimicrobial, an oncostatic, a central nervous system sedative and the anti-inflammatory effect. Chelidonic acid evokes antidepressant-like effect through the up-regulation of BDNF in forced swimming test. Chelidonic acid administration significantly increased the mRNA expression of hippocampal estrogen receptor-β. The levels of hippocampal interleukin (IL)-1β, IL-6, and tumor necrosis factor-α were effectively attenuated by the administration of chelidonic acid. In addition, chelidonic acid significantly increased the levels of 5-hydroxytryptamine (serotonin), dopamine, and norepinephrine compared with those levels for the mice that were administered distilled water in the hippocampus. Chelidonic acid might serve as a new therapeutic strategy for the regulation of depression associated with inflammation.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3758 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4062982 |
1.2 µM [Ki] | ||
Target ID: CHEMBL4321 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22687399 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Tracer studies with 13C-labeled carbohydrates in cultured plant cells. Retrobiosynthetic analysis of chelidonic acid biosynthesis. | 2001 May |
|
Cationic, neutral and anionic metal(II) complexes derived from 4-oxo-4H-pyran-2,6-dicarboxylic acid (chelidonic acid). | 2007 May |
|
Effect of mucilage from yam on activation of lymphocytic immune cells. | 2007 Summer |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27620504
Rats: In mast cell degranulation studies, ovalbumin immunized and challenged rats, chelidonic acid (1, 3 and 10mg/kg, i.p.) dose relatedly prevented ovalbumin challenge induced mast cell degranulation by differing degrees when compared with the vehicle-treated group, and these effects were comparable with prednisolone (10mg/kg).
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27620504
GAD was preincubated for 30 min with 1 mM chelidonic
acid (CA), 5 mM glutamate (GLU), and 5 mM
glutamate + 1 mM chelidonic acid (GLU + CA). Kinetic analysis showed that chelidonic acid was competitive with glutamate with a K; of 1.2 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:50:29 GMT 2023
by
admin
on
Fri Dec 15 18:50:29 GMT 2023
|
Record UNII |
T33U4W5K6O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
202-749-0
Created by
admin on Fri Dec 15 18:50:29 GMT 2023 , Edited by admin on Fri Dec 15 18:50:29 GMT 2023
|
PRIMARY | |||
|
Chelidonic acid
Created by
admin on Fri Dec 15 18:50:29 GMT 2023 , Edited by admin on Fri Dec 15 18:50:29 GMT 2023
|
PRIMARY | |||
|
T33U4W5K6O
Created by
admin on Fri Dec 15 18:50:29 GMT 2023 , Edited by admin on Fri Dec 15 18:50:29 GMT 2023
|
PRIMARY | |||
|
DTXSID30243928
Created by
admin on Fri Dec 15 18:50:29 GMT 2023 , Edited by admin on Fri Dec 15 18:50:29 GMT 2023
|
PRIMARY | |||
|
99-32-1
Created by
admin on Fri Dec 15 18:50:29 GMT 2023 , Edited by admin on Fri Dec 15 18:50:29 GMT 2023
|
PRIMARY | |||
|
C046884
Created by
admin on Fri Dec 15 18:50:29 GMT 2023 , Edited by admin on Fri Dec 15 18:50:29 GMT 2023
|
PRIMARY | |||
|
3979
Created by
admin on Fri Dec 15 18:50:29 GMT 2023 , Edited by admin on Fri Dec 15 18:50:29 GMT 2023
|
PRIMARY | |||
|
7431
Created by
admin on Fri Dec 15 18:50:29 GMT 2023 , Edited by admin on Fri Dec 15 18:50:29 GMT 2023
|
PRIMARY | |||
|
m3321
Created by
admin on Fri Dec 15 18:50:29 GMT 2023 , Edited by admin on Fri Dec 15 18:50:29 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |